Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
NXP Semiconductors
NXPI
AU Stock MarketDetailed Quotes
LTR Pharma Ltd (LTP)
- 0.485
- -0.025-4.90%
20min DelayPost Close Trading Jul 28 15:30 AET
88.16MMarket Cap-14.70P/E (Static)
0.510High0.480Low286.68KVolume0.510Open0.510Prev Close140.20KTurnover0.81052wk High0.27%Turnover Ratio181.78MShares0.31552wk Low-0.05EPS TTM51.71MFloat Cap2.150Historical HighLossP/E (Static)106.62MShs Float0.235Historical Low-0.033EPS LYR5.88%Range %--Dividend TTM3.28P/B1Lot Size--Div Yield TTM
LTP Stock Chart
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
LTP Orderflow
Unit: --
LTP Orderflow Trend
IntradayDayWeekMonth
No Data
LTR Pharma Ltd (LTP) News
Shed and LTR Pharma Execute Definitive Commercial Agreement to Bring ROXUS to Patients Across the United States
LTR Pharma Executes Definitive US Distribution Agreement With Shed Holdings for ROXUS, Shares Up 11%
LTR Pharma Gets Ethics Committee Approval for Trial of Intranasal Spray in Patients With Oesophageal Motility Disorders
LTR Pharma Establishes Exclusive US Pharmacy Fulfilment Rights for Erectile Dysfunction Product, Shares Jump 22%
Shed Secures Exclusive U.S. Telehealth Access to ROXUS, a Rapid-Acting Intranasal Treatment for Erectile Dysfunction Through LTR Pharma
LTR Pharma Says Interim Phase Two Data for Erectile Dysfunction Treatment Candidate Shows Rapid Time to Peak Concentration, Shares Jump 28%
LTR Pharma Ltd (LTP) Stock Forum
$LTR Pharma Ltd (LTP.AU)$ release
The Quarter delivered two of our most significant milestones to date.
Clinically, interim data from the SPONTAN® Phase II pharmacokinetic study demonstrated a median Tmax of 10 minutes, compared with 60 minutes for oral vardenafil. The study also demonstrated no drug accumulation following repeat dosing and a consistent safety profile. Final statistical analysis is expected in Q3 CY2026.
Alongside this progress, we secured the two core commercial agreements r...
The Quarter delivered two of our most significant milestones to date.
Clinically, interim data from the SPONTAN® Phase II pharmacokinetic study demonstrated a median Tmax of 10 minutes, compared with 60 minutes for oral vardenafil. The study also demonstrated no drug accumulation following repeat dosing and a consistent safety profile. Final statistical analysis is expected in Q3 CY2026.
Alongside this progress, we secured the two core commercial agreements r...
17 July 2026
Highlights
• Definitive commercial agreement executed with Shed, a leading U.S. direct-to-consumer (DTC) telehealth
platform
• Converts the previously announced binding Term Sheet into a comprehensive long-form commercial
agreement
• Establishes the commercial framework for the planned U.S. commercialisation of ROXUS® through Shed’s
dedicated men’s health platform, Mavrox
• Shed has committed to support delivery of not less than 150,000 ROXUS units during the first 12 months
followi...
Highlights
• Definitive commercial agreement executed with Shed, a leading U.S. direct-to-consumer (DTC) telehealth
platform
• Converts the previously announced binding Term Sheet into a comprehensive long-form commercial
agreement
• Establishes the commercial framework for the planned U.S. commercialisation of ROXUS® through Shed’s
dedicated men’s health platform, Mavrox
• Shed has committed to support delivery of not less than 150,000 ROXUS units during the first 12 months
followi...
2
$LTR Pharma Ltd (LTP.AU)$ LTR Pharma Expands Intranasal Platform
into Gastrointestinal Disorders.
LTR Pharma has announced that OROFLOW® has become the first gastrointestinal application of the Company's proprietary intranasal platform to enter
formal clinical evaluation.
into Gastrointestinal Disorders.
LTR Pharma has announced that OROFLOW® has become the first gastrointestinal application of the Company's proprietary intranasal platform to enter
formal clinical evaluation.
1
$LTR Pharma Ltd (LTP.AU)$
look at her gooo
look at her gooo
1
Read more
Market Insights
Hot AI Stocks Hot AI Stocks
AI stocks surge on chip demand and cloud security breakthroughs; future growth hinges on autonomous driving and global computing infrastructure AI stocks surge on chip demand and cloud security breakthroughs; future growth hinges on autonomous driving and global computing infrastructure